Hitchhiking is a phenomenon of cruising on surfaces. Inspired by this process, biomimetic delivery systems leveraging the intrinsic ability of circulatory cells to target tumors exhibit considerable potential in cancer theranostics. Besides human circulatory cell‐mediated hitchhiking, bacteria‐driven hitchhiking strategies also manifest promise in cancer therapy. Such tactics are primarily built using nonpathogenic invasive bacteria with tumor homing capabilities. The chemotherapeutic cargos are hitchhiked onto the circulatory cells or bacterial spores for tumor‐targeted delivery. By integrating the benefits of such cells and therapeutic cargo, numerous efficient delivery systems that implement the notion of hitchhiking for cancer therapy are generated. Following an overview of several hitchhiking concepts, this article reviews various cellular and bacterial hitchhiking approaches for cancer treatment. Additionally, the challenges and prospects in the field of cancer theranostics related to hitchhiking are also discussed.

One of the most effective cancer therapies, cancer immunotherapy has produced outstanding outcomes in the field of cancer treatment. However, the cost is excessive, which limits its applicability. A smart way to address this issue would be to apply the knowledge gained through immunotherapy to develop strategies for the immunoprevention of cancer. The use of cancer vaccines is one of the most popular methods of immunoprevention. This paper reviews the technologies and processes that support the advantages of cancer immunoprevention over traditional cancer immunotherapies. Nanoparticle drug delivery systems and nanoparticle-based nano-vaccines have been employed in the past for cancer immunotherapy. This paper outlines numerous immunoprevention strategies and how nanotechnology can be applied in immunoprevention. To comprehend the non-clinical and clinical evaluation of these cancer vaccines through clinical studies is essential for acceptance of the vaccines.

Rising awareness of the risks regarding chemical formulations and the surging need for eco-friendly inputs in sustainable agriculture have driven the use of bacterial biocontrol agents to the frontline of plant protection. Bacterial biocontrol agents (BBCAs) have been preferred as feasible alternatives to synthetic formulations due to their increased specificity and safety. Nanotechnology has facilitated the better addressing of product development and performance concerns related to BBCAs. Leveraging nanotechnology in the synthesis of novel nanomaterials with amended properties at the nanoscale has offered efficient and ecologically sound nanoformulations such as nanobiopesticides. The nanobiopesticides of bacterial origin, known as bacteria premised nanobiopesticides (B-NBPs), are efficient alternatives to agrochemicals. The B-NBPs include living or nonliving bacterial nanoformulations or nanoparticles synthesized using bacteria (BNPs) as the nanofactories. The B-NBPs were synthesized using high-pressure homogenization (HPH), jet milling, and hammer milling, giving rise to competent bacterial nanoformulations of size ranging from 250 to 500 nm. Following an overview of bacteria-based nanobiopesticides (B-NBPs) employed to prevent/treat plant diseases, the article highlights the role of BBCA's role in plant protection as well as its antagonistic mechanisms. Further, the concept of B-NBPs, concentrating on Bacillus thuringensis-driven forms, is reviewed. The review then briefly explains the significance of BNPs in plant infection management. Finally, the concerns related to the efficacy of B-NBPs along with the prospects are also described.